New SPECT and PET Radiopharmaceuticals for Imaging Cardiovascular Disease

Table 11

SPECT and PET Radiopharmaceutical for Imaging Apoptosis.

	^99mTc-HYNIC(Tricine)2-Annexin V (^99mTc-Annexin-V); (i) example of a tricine derivatized ^99mTc-HYNIC based chelate appended to annexin-V; (ii) annexin-V binds to phosphatidylserine exposed on the surface of cells undergoing apoptosis (calcium dependent); (iii) ^99mTc-HYNIC-Annexin-V derivatives have high renal and hepatic uptake with unfavourable radiation dosimetry to these organs [101]
	p-^18F-Fluorobenzyltriphenylphosphonium (^18F-FBnTP); (i) a cationic and sufficiently lipophilic compound that passively diffuses across cell membranes of cardiac myocytes; (ii) accumulation in mitochondria driven by negative membrane potential
	^18F-(S)-1-((1-(2-Fluoroethyl)-1H-[1,2,3]-Triazol-4-yl)methyl)-5-(2(2,4-Difluorophenoxymethyl)-Pyrrolidine-1-sulfonyl)Isatin (^18F-ICMT-11); (i) caspase-3-specific PET tracer for apoptosis imaging; (ii) first in human studies in 8 healthy volunteers (4 women and 4 men) confirmed a safe PET tracer with a favourable dosimetry profile, biodistribution and stability [102]
	^18F-2-(5-Fluoropentyl)-2-Methylmalonic acid (^18F-ML-10); (i) PET tracer for apoptosis imaging; (ii) first in human studies in 8 healthy volunteers also showed favourable dosimetry, biodistribution, stability and safety [103]